The development
What happened
Google DeepMind has introduced AlphaGenome 2, an AI model that predicts how DNA may affect gene regulation in a specified cell type or biological state. It is available for non-commercial research through the AlphaGenome API and Colab tutorials; commercial access is a private preview. DeepMind explicitly says the model is not validated or approved for clinical or diagnostic use.
Key facts
The model takes a DNA sequence of up to one million base pairs together with one biological condition at a time, such as a tissue, cell type or cell state. This condition-specific approach differs from the original AlphaGenome model's parallel predictions of bulk measurements.
DeepMind says training combined bulk and single-cell human and mouse data, including more than 107 million cell profiles spanning 68 tissues. The model predicts gene expression, chromatin features and histone marks, and adds DNA methylation predictions.
According to the announcement, researchers can condition predictions on new cell states using RNA-sequencing profiles without retraining the model. That is a reported modeling capability, not proof that a predicted regulatory effect is biologically causal.
The 11 November release provides non-commercial research access and tutorials. Commercial access is limited to a private preview; proposed Antigravity agent skills are described as future work rather than an available feature.
The context
Why it matters
Gene regulation depends on biological context, so cell-specific predictions could help researchers prioritize hypotheses about non-coding DNA variants. The announcement does not make the model a diagnostic tool, establish clinical benefit or replace experimental validation. This article reports the developer's release claims, not an independent model evaluation.